UY34587A - Formulaciones estabilizadas que contienen anticuerpos antiang2 - Google Patents
Formulaciones estabilizadas que contienen anticuerpos antiang2Info
- Publication number
- UY34587A UY34587A UY0001034587A UY34587A UY34587A UY 34587 A UY34587 A UY 34587A UY 0001034587 A UY0001034587 A UY 0001034587A UY 34587 A UY34587 A UY 34587A UY 34587 A UY34587 A UY 34587A
- Authority
- UY
- Uruguay
- Prior art keywords
- antiang2
- antibodies
- formulations containing
- stabilized formulations
- stabilized
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 241000950314 Figura Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo que se une específicamente a angiopoyetina 2 (Ang-2). Las formulaciones pueden contener, además de un anticuerpo anti-Ang-2, al menos un aminoácido, al menos un carbohidrato, o al menos un tensioactivo no iónico. Las formulaciones farmacéuticas de la presente invención exhiben un grado sustancial de estabilidad del anticuerpo tras el almacenamiento durante varios meses y después de haber sido sometido a esfuerzo térmico y a otros esfuerzos físicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261589427P | 2012-01-23 | 2012-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34587A true UY34587A (es) | 2013-07-31 |
Family
ID=47633582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034587A UY34587A (es) | 2012-01-23 | 2013-01-23 | Formulaciones estabilizadas que contienen anticuerpos antiang2 |
Country Status (23)
Country | Link |
---|---|
US (1) | US9402898B2 (es) |
EP (1) | EP2807190B1 (es) |
JP (1) | JP6113756B2 (es) |
KR (1) | KR102063028B1 (es) |
CN (1) | CN104169299B (es) |
AR (1) | AR089787A1 (es) |
AU (1) | AU2013212587B2 (es) |
BR (1) | BR112014017882A2 (es) |
CA (1) | CA2861062A1 (es) |
CL (1) | CL2014001930A1 (es) |
EA (1) | EA033387B1 (es) |
HK (1) | HK1204631A1 (es) |
IL (1) | IL233482B (es) |
JO (1) | JO3533B1 (es) |
MA (1) | MA35904B1 (es) |
MX (1) | MX357393B (es) |
MY (1) | MY164611A (es) |
NZ (1) | NZ627859A (es) |
PH (1) | PH12014501628A1 (es) |
SG (1) | SG11201403792TA (es) |
TW (1) | TWI615149B (es) |
UY (1) | UY34587A (es) |
WO (1) | WO2013112438A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6113756B2 (ja) | 2012-01-23 | 2017-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗ang2抗体を含有する安定化製剤 |
US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
WO2014151834A2 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
KR102349370B1 (ko) | 2014-05-26 | 2022-01-10 | 삼성전자주식회사 | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 |
WO2015184325A2 (en) * | 2014-05-30 | 2015-12-03 | New England Biolabs, Inc. | Deglycosylation reagents and methods |
CA2963091A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
CA2964470A1 (en) * | 2014-10-17 | 2016-04-21 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
US11058769B2 (en) * | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
MX2018015960A (es) * | 2016-06-30 | 2019-03-21 | Celltrion Inc | Formulacion farmaceutica liquida estable. |
FR3054444A1 (fr) * | 2016-07-29 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnf alpha |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
WO2018122053A1 (en) * | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Anti-angiopoietin-2 antibody formulation |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
IL270267B1 (en) | 2017-05-06 | 2024-02-01 | Regeneron Pharma | Methods for treating eye disorders with APLNR antagonists and VEGF inhibitors |
MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
US20190225689A1 (en) * | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
JP7349998B2 (ja) | 2018-01-31 | 2023-09-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法 |
TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
TW202323813A (zh) | 2018-03-19 | 2023-06-16 | 美商再生元醫藥公司 | 微晶片毛細管電泳分析及試劑 |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
MX2021002279A (es) | 2018-08-27 | 2021-05-27 | Regeneron Pharma | Uso de espectroscopia raman en la purificacion corriente abajo. |
EP3775926A1 (en) | 2018-08-30 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
WO2020150492A1 (en) | 2019-01-16 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
US20220204603A1 (en) * | 2019-02-25 | 2022-06-30 | Pharmabcine Inc. | Anti-ang2 antibody and use thereof |
US11730812B2 (en) * | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
CN113785203A (zh) | 2019-05-13 | 2021-12-10 | 里珍纳龙药品有限公司 | 改进的竞争性配体结合测定 |
EP4034870A1 (en) | 2019-09-24 | 2022-08-03 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
BR122023021668A2 (pt) | 2020-01-21 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Método para determinar a estabilidade de uma proteína de interesse |
EP4178983A1 (en) * | 2020-07-08 | 2023-05-17 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ctla-4 antibodies |
KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
JP2023551446A (ja) | 2020-11-25 | 2023-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水膜乳化を使用した持続放出製剤 |
KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
WO2022204728A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
IL308864A (en) | 2021-06-01 | 2024-01-01 | Regeneron Pharma | In-house capillary electrophoresis tests and reagents |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
WO2023044139A1 (en) | 2021-09-20 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
US20230116199A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
CA3230985A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Ph meter calibration and correction |
WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
RU2195960C2 (ru) | 1998-03-17 | 2003-01-10 | Тугаи Сейяку Кабусики Кайся | Профилактический или терапевтический агент для лечения воспалительных заболеваний кишечника, содержащий в качестве активного ингредиента антагонист il-6 |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
WO2002013860A1 (fr) | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
AU2003219958B2 (en) | 2002-02-27 | 2006-01-05 | Immunex Corporation | Polypeptide formulation |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
CN1771053B (zh) * | 2003-02-10 | 2012-10-03 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
RU2404992C2 (ru) * | 2004-10-19 | 2010-11-27 | Эмджен Инк. | Ангиопоэтин-2-специфические связывающие агенты |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
PT1838733E (pt) | 2004-12-21 | 2011-12-13 | Medimmune Ltd | Anticorpos direccionados a angiopoietina-2 e respectivos usos |
EP3195874A1 (en) | 2005-03-25 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
CA2712000A1 (en) * | 2008-01-28 | 2009-08-06 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
IT1396433B1 (it) * | 2009-11-16 | 2012-11-23 | Rolic Invest Sarl | Impianto eolico per la generazione di energia elettrica e metodo per realizzare un pilone del suddetto impianto eolico. |
EP3721904B1 (en) | 2009-11-20 | 2021-10-13 | Biocon Limited | Formulations of t1h antibody |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
EP3354280B1 (en) | 2010-10-06 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
JP6113756B2 (ja) | 2012-01-23 | 2017-04-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗ang2抗体を含有する安定化製剤 |
US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2013
- 2013-01-22 JP JP2014553508A patent/JP6113756B2/ja not_active Expired - Fee Related
- 2013-01-22 KR KR1020147023205A patent/KR102063028B1/ko active IP Right Grant
- 2013-01-22 MY MYPI2014001985A patent/MY164611A/en unknown
- 2013-01-22 CA CA2861062A patent/CA2861062A1/en not_active Abandoned
- 2013-01-22 AU AU2013212587A patent/AU2013212587B2/en not_active Ceased
- 2013-01-22 WO PCT/US2013/022473 patent/WO2013112438A1/en active Application Filing
- 2013-01-22 NZ NZ627859A patent/NZ627859A/en not_active IP Right Cessation
- 2013-01-22 JO JOP/2013/0020A patent/JO3533B1/ar active
- 2013-01-22 MX MX2014008874A patent/MX357393B/es active IP Right Grant
- 2013-01-22 CN CN201380006367.8A patent/CN104169299B/zh not_active Expired - Fee Related
- 2013-01-22 SG SG11201403792TA patent/SG11201403792TA/en unknown
- 2013-01-22 EA EA201491414A patent/EA033387B1/ru unknown
- 2013-01-22 BR BR112014017882A patent/BR112014017882A2/pt not_active Application Discontinuation
- 2013-01-22 EP EP13702556.5A patent/EP2807190B1/en active Active
- 2013-01-22 US US13/746,669 patent/US9402898B2/en active Active
- 2013-01-23 UY UY0001034587A patent/UY34587A/es not_active Application Discontinuation
- 2013-01-23 TW TW102102503A patent/TWI615149B/zh not_active IP Right Cessation
- 2013-01-23 AR ARP130100204A patent/AR089787A1/es not_active Application Discontinuation
-
2014
- 2014-07-02 IL IL233482A patent/IL233482B/en active IP Right Grant
- 2014-07-15 PH PH12014501628A patent/PH12014501628A1/en unknown
- 2014-07-22 CL CL2014001930A patent/CL2014001930A1/es unknown
- 2014-08-07 MA MA37279A patent/MA35904B1/fr unknown
-
2015
- 2015-06-01 HK HK15105209.9A patent/HK1204631A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150000873A (ko) | 2015-01-05 |
AR089787A1 (es) | 2014-09-17 |
IL233482B (en) | 2019-06-30 |
CN104169299A (zh) | 2014-11-26 |
SG11201403792TA (en) | 2014-10-30 |
TWI615149B (zh) | 2018-02-21 |
WO2013112438A1 (en) | 2013-08-01 |
JP6113756B2 (ja) | 2017-04-12 |
CN104169299B (zh) | 2018-06-05 |
CL2014001930A1 (es) | 2014-10-03 |
MA35904B1 (fr) | 2014-12-01 |
US20130186797A1 (en) | 2013-07-25 |
KR102063028B1 (ko) | 2020-01-07 |
EA201491414A1 (ru) | 2014-12-30 |
TW201343177A (zh) | 2013-11-01 |
BR112014017882A2 (pt) | 2017-06-27 |
EA033387B1 (ru) | 2019-10-31 |
AU2013212587B2 (en) | 2017-07-20 |
NZ627859A (en) | 2015-09-25 |
PH12014501628B1 (en) | 2014-10-13 |
HK1204631A1 (en) | 2015-11-27 |
PH12014501628A1 (en) | 2014-10-13 |
EP2807190A1 (en) | 2014-12-03 |
JO3533B1 (ar) | 2020-07-05 |
US9402898B2 (en) | 2016-08-02 |
CA2861062A1 (en) | 2013-08-01 |
MY164611A (en) | 2018-01-30 |
JP2015505539A (ja) | 2015-02-23 |
IL233482A0 (en) | 2014-08-31 |
MX2014008874A (es) | 2014-09-01 |
EP2807190B1 (en) | 2018-12-26 |
MX357393B (es) | 2018-07-06 |
AU2013212587A1 (en) | 2014-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34587A (es) | Formulaciones estabilizadas que contienen anticuerpos antiang2 | |
UY34228A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9 | |
UY34456A (es) | Anticuerpos anti-il-36r | |
UY34779A (es) | Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen | |
UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
UY34582A (es) | Anticuerpos anti-cxcr3 | |
UY34836A (es) | Nuevo organismos | |
UY34817A (es) | Tienopirimidinas | |
UY34961A (es) | Nanocarbono que contiene caucho natural | |
UY34654A (es) | Inhibidores de la beta-secretasa | |
BR112014001219A2 (pt) | perfume | |
UY33906A (es) | Composiciones herbicidas que comprenden topramezona | |
UY4210Q (es) | Silla | |
BR112013025866A2 (pt) | formulações com viscosidade reduzida | |
UY4281Q (es) | Juguera | |
AU357215S (en) | Positioning element for construction toy | |
CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
BR112015003294A2 (pt) | caldeira de armazenamento | |
AR097668A1 (es) | Colorante-polímero | |
BR112014000165A2 (pt) | dispensador | |
UY4237Q (es) | Taburete | |
CL2011000572S1 (es) | Contenedor. | |
CL2012003679S1 (es) | Licuadora | |
TN2011000372A1 (fr) | جهاز مراقبة وتحكم في استهلاك المياه | |
TN2011000399A1 (fr) | دراجة كهربائية ذات شحن الي |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20200914 |
|
RDES | Application refused |
Effective date: 20231211 |